Antibody Engineering & Therapeutics US is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.


James Ernst, Ph.D.
Senior Director, Head of Development Sciences at Xencor


James Ernst received his Ph.D. in Biophysical Chemistry from Yale University and took post-Doctoral Studies in Molecular and Cell biology at the Stanford University Medical School. He is currently a Senior Scientist in the Protein Sciences division of the Genentech Research and Early Development organization. He has more than 15 years of experience supporting all stages of therapeutic development from target identification to clinical validation. He is an expert in biochemical assay development, protein-protein binding, structure function relationships and antibody production. He has worked with and lead both large and small molecule therapeutic discovery teams where his work has contributed meaningfully to the development of brain penetrant antibodies and the development antibodies targeting amyloid proteins treatment of neurodegenerative disease, anti-CD20 antibodies for the treatment of Multiple Sclerosis and an FGF21 mimetic antibody for the treatment of type II diabetes. Most recently his research has focused on the interspecies translatability and stability of engineered variants of the antibody Fc-effector region.

James Ernst, Ph.D.'s Network

Agenda Sessions

  • Co-Chairs Remarks